Home Tags Antibody-drug Conjugates

Tag: Antibody-drug Conjugates

Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering

In a statement earlier today, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, confirmed that it has acquired Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADCs).

Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...

Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.

Mirvetuximab Soravtansine Demonstrates Overall Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer

Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.

ZB131 ADC Induce Potent Anti-tumor Activity CSP-expressing Tumors

Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, is a potentially promising target for the development of novel antibody-drug conjugates (ADC).

FDA Grants Fast Track Designation to DB-1303 for the Treatment of...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DB-1303 a novel antibody-drug conjugates for the treatment of patients with advanced, recurrent or metastatic endometrial carcinoma with HER2 over-expression who have progressed on or after standard systemic treatment.
ADC Bio's PD Lab

Opportunities for ADC Development and Manufacturing

At the 2022 World ADC Conference in San Diego, Stewart Mitchell, Executive Vice President and site head of Sterling Pharma Solutions' Deeside, U.K. facility, presented a case study on the development and GMP manufacture at the site.

Bpifrance Supports Diaccurate in the Development of Novel Payloads for ADCs

French biotech company Diaccurate, specialized in the development of new therapies in oncology, has received from grant from the Banque publique d'investissement (Bpifrance), a French public investment bank, to help the company fund its DIACC2020 Program.

Advances in the Development of Dual-Drug Antibody Drug Conjugates

Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).

Stable, Site-Specific ADC Conjugation with SMARTag® Technology and Innovative Linker

Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.